Cancer: Key Facts, Diagnosis, and Treatment Modalities

Miss. Madhura Suresh Patil
Guide Name - Mahesh Thorat
Bachelor of Pharmacy,
Womens College of Pharmacy Peth Vadgaon Dist Kolhapur (Maharashtra) 416112

ABSTRACT
Cancer is characterized by proliferation of cells that have managed to evade central endogenous control mechanisms. Cancers are grouped according to their organ or tissue of origin, but increasingly also based on molecular characteristics of the respective cancer cells. Due to the rapid technological advances of the last years, it is now possible to analyze the molecular makeup of different cancer types in detail within short time periods. The accumulating knowledge about development and progression of cancer can be used to develop more precise diagnostics and more effective and/or less toxic cancer therapies. In the long run, the goal is to offer to every cancer patient a therapeutic regimen that is tailored to his individual disease and situation in an optimal way.
General Cancer Keywords
- Cancer Oncology Tumor Neoplasm Malignancy
- Carcinogenesis TumorigenesisCancer biology Cancer progression

I.   INTRODUCTION

Cancer remains one of the most complex and formidable challenges in modern medicine. Characterized by uncontrolled cell proliferation, invasion, and metastasis, cancer encompasses more than 100 distinct diseases affecting virtually every organ system. Despite decades of research and significant progress in diagnostics, therapeutic strategies, and public health policies, cancer continues to be a leading cause of morbidity and mortality worldwide.

The global burden of cancer is increasing, driven by aging populations, environmental exposures, lifestyle factors, and genetic predispositions. According to the World Health Organization (WHO), the number of new cancer cases is expected to rise substantially in the coming decades, posing major challenges to healthcare systems, especially in low- and middle- income countries.

At the molecular level, cancer is driven by a multitude of genetic and epigenetic alterations that disrupt normal regulatory pathways governing cell growth, apoptosis, and DNA repair. These changes culminate in the hallmarks of cancer, as described by Hanahan and Weinberg, including sustained proliferative signaling, evasion of growth suppressors, resistance to cell death, and activation of invasion and metastasis.

Recent advances in cancer biology, genomics, and immunology have transformed our understanding of tumor development and progression, paving the way for innovative diagnostic tools and personalized treatment strategies. The advent of precision medicine, immunotherapy, and targeted therapies has improved survival and quality of life for many cancer patients, although challenges such as drug resistance, tumor heterogeneity, and adverse effects remain.

This comprehensive review aims to synthesize the current knowledge of cancer pathogenesis, classification, diagnostic approaches, and therapeutic modalities. Emphasis will be placed on recent breakthroughs, ongoing challenges, and future directions in cancer research and treatment. By integrating insights across disciplines, this paper seeks to provide a holistic overview of the state of cancer science and its implications for clinical practice and public health.

Types of Cancer
- Breast cancer
- Lung cancer
- Colorectal cancer
- Prostate cancer
- Pancreatic cancer

Breast Cancer: Detailed Information
1. **Definition**
- Leukemia
- Lymphoma
- Skin cancer (melanoma)

- Brain tumors (glioblastoma)

Breast cancer is a malignant tumor that originates in the cells of the breast, most commonly in the ducts (ductal carcinoma) or lobules (lobular carcinoma). It can affect both women and men, although it is far more common in women.

2. Epidemiology
- **Incidence**: Breast cancer is the most common cancer in women globally.
- **Mortality**: It is a leading cause of cancer-related death in women.
- **Age**: Risk increases with age; most diagnoses occur after age 50.
- **Geographic variation**: Higher incidence in developed countries, though mortality is often higher in low- and middle-income countries due to limited access to screening and treatment.

3. Types of Breast Cancer
A. Based on Invasiveness
- **Non-invasive (in situ)**:
- Ductal carcinoma in situ (DCIS): Confined to milk ducts.
- Lobular carcinoma in situ (LCIS): A risk factor, not a true cancer.
- **Invasive (infiltrating)**:
- Invasive ductal carcinoma (IDC): Most common (70–80%).
- Invasive lobular carcinoma (ILC): 10–15% of cases.

B. Molecular Subtypes (based on receptor status)
- **Hormone receptor-positive (HR+)**:

- Estrogen receptor (ER) and/or progesterone receptor (PR) positive.
- **HER2-positive**: Overexpression of human epidermal growth factor receptor 2.
- **Triple-negative breast cancer (TNBC)**:
- Lacks ER, PR, and HER2.
- More aggressive; limited treatment options.

4. Risk Factors
- **Genetic**:
- BRCA1 and BRCA2 mutations significantly increase risk.
- Family history of breast or ovarian cancer.

- **Hormonal and Reproductive**:
- Early menarche, late menopause, late age at first childbirth, nulliparity.
- Hormone replacement therapy (HRT).
- **Lifestyle**:
- Obesity, alcohol consumption, physical inactivity.
- **Environmental**:
- Radiation exposure.
- **Other**:
- Dense breast tissue, previous breast disease.

5. Pathophysiology
Breast cancer arises from genetic and epigenetic alterations that lead to:
- Loss of tumor suppressor function (e.g., TP53, BRCA1/2).
- Activation of oncogenes (e.g., HER2).
- Dysregulation of cell signaling pathways (e.g., PI3K/AKT, MAPK).
- Escape from immune surveillance.
- Angiogenesis and metastasis, especially to bone, liver, lung, and brain.

6. Diagnosis
A. Screening
- **Mammography**: Gold standard for early detection.
- **Ultrasound/MRI**: Supplemental, especially in high-risk patients.

B. Diagnostic Workup
- **Clinical breast exam**.
- **Imaging (mammogram, ultrasound, MRI)**.
- **Biopsy**: Core needle biopsy is most common.
- **Histopathology**: Determines grade, type, receptor status (ER/PR/HER2).

C. Staging

- **TNM System**: Tumor size (T), lymph node involvement (N), metastasis (M).
- **Stages I–IV**: From early/localized to metastatic disease.

7. Treatment
A. Surgery
- **Breast-conserving surgery (lumpectomy)**.
- **Mastectomy** (partial or total).
- **Sentinel lymph node biopsy or axillary dissection**.

B. Radiation Therapy
- Often used after surgery to reduce recurrence risk.

C. Systemic Therapies
- **Hormonal therapy** (for ER/PR+):
- Tamoxifen, aromatase inhibitors.
- **Targeted therapy**:
- Trastuzumab (Herceptin) for HER2+.
- **Chemotherapy**:
- Used for TNBC, high-grade tumors, or node-positive disease.
- **Immunotherapy**:
- Atezolizumab and pembrolizumab for some TNBC cases.

8. Prognosis
- Depends on stage at diagnosis, molecular subtype, age, and response to treatment.
- 5-year survival:
- ~99% (localized),
- ~86% (regional),
- ~29% (metastatic).

9. Recent Advances
- **Genomic profiling (e.g., Oncotype DX)** to guide chemotherapy decisions.
- **Liquid biopsies** for monitoring minimal residual disease.
- **PARP inhibitors** for BRCA-mutated cancers.
- **Antibody-drug conjugates (e.g., T-DM1)**.
- **CDK4/6 inhibitors** in hormone receptor-positive advanced cancer.
- **AI-based diagnostics** and decision support.

10. Prevention and Risk Reduction
- **Lifestyle modification** (diet, exercise, alcohol moderation).
- **Chemoprevention**: Tamoxifen or raloxifene for high-risk women.

- **Prophylactic surgery** (mastectomy, oophorectomy) for BRCA mutation carriers.
- **Genetic counseling and testing**.

Lung Cancer: Comprehensive Overview

1. Definition
Lung cancer is a malignant tumor originating from the epithelial cells of the respiratory tract. It is the **leading cause of cancer-related mortality** worldwide in both men and women, primarily due to its often late diagnosis and aggressive nature.

2. Epidemiology
- **Global incidence**: Over 2.2 million new cases and ~1.8 million deaths annually.
- **Gender differences**: More common in men, but rising in women due to increased tobacco use.
- **Risk by region**: Higher incidence in industrialized countries; urban areas have higher rates due to pollution.
- **Survival rate**: 5-year survival remains poor (~20%) due to late-stage presentation.

3. Classification of Lung Cancer
A. Based on Histology
1. **Non-Small Cell Lung Cancer (NSCLC)** – ~85% of cases
- **Adenocarcinoma** (most common in non-smokers and women)
- **Squamous cell carcinoma**
- **Large cell carcinoma**

   Small Cell Lung Cancer (SCLC) – ~15% of cases
- Highly aggressive with early metastasis
- Strongly associated with smoking

B. Based on Molecular Subtypes (mainly for NSCLC)
- **EGFR mutations** (common in Asian populations and non-smokers)
- **ALK rearrangements**
- **ROS1 fusions**
- **KRAS mutations**
- **PD-L1 expression levels** (important for immunotherapy eligibility)

4. Risk Factors
- **Tobacco smoking** (primary cause – accounts for ~85% of cases)
- **Secondhand smoke exposure**
- **Environmental exposures**: radon gas, asbestos, air pollution, heavy metals (arsenic, chromium)
- **Occupational exposure**: construction, mining, chemical industries
- **Genetic predisposition**
- **Chronic lung disease**: COPD, pulmonary fibrosis

5. Pathophysiology
- **Initiation**: DNA mutations caused by carcinogens (e.g., tobacco smoke)
- **Progression**: Activation of oncogenes (e.g., EGFR, KRAS), inactivation of tumor suppressor genes (e.g., TP53, RB)
- **Tumor growth**: Uncontrolled proliferation, angiogenesis, and evasion of apoptosis
- **Metastasis**: Commonly to brain, bone, liver, and adrenal glands

6. Clinical Presentation
Local Symptoms
- Persistent cough
- Hemoptysis (coughing up blood)
- Dyspnea (shortness of breath)
- Chest pain

Systemic Symptoms
- Weight loss
- Fatigue
- Anorexia
- Fever

Paraneoplastic Syndromes
- **SIADH** (Syndrome of Inappropriate Antidiuretic Hormone Secretion)
- **Cushing's syndrome**
- **Hypercalcemia**
- **Lambert-Eaton syndrome**

7. Diagnosis
A. Imaging
- **Chest X-ray**: Often the first test
- **CT scan**: Better visualization of tumor size and lymph node involvement
- **PET-CT**: Evaluates metabolic activity and metastasis
- **MRI**: Brain metastases

B. Tissue Diagnosis
- **Bronchoscopy with biopsy**
- **CT-guided needle biopsy**
- **Endobronchial ultrasound (EBUS)**
- **Pleural fluid cytology** (if effusion present)

C. Molecular Testing
- EGFR, ALK, ROS1, KRAS, BRAF, MET, RET, NTRK mutations
- PD-L1 expression for immunotherapy selection

8. Staging
- **NSCLC**: TNM classification (Tumor size, Node involvement, Metastasis)
- **SCLC**: Limited stage (confined to one hemithorax) or extensive stage (spread beyond one hemithorax)

9. Treatment
A. NSCLC Treatment
- **Early-stage (I–II)**:
- Surgical resection (lobectomy or pneumonectomy)
- Adjuvant chemotherapy/radiation as needed
- **Locally advanced (Stage III)**:
- Chemoradiotherapy
- Immunotherapy (e.g., durvalumab after chemoradiation)
- **Advanced/metastatic (Stage IV)**:
- **Targeted therapy**:
- EGFR inhibitors (osimertinib, erlotinib)
- ALK inhibitors (alectinib, lorlatinib)
- ROS1 inhibitors (crizotinib)
- **Immunotherapy**:
- Anti-PD-1/PD-L1 (nivolumab, pembrolizumab, atezolizumab)
- May be combined with chemotherapy
- **Chemotherapy**: Platinum-based doublets

B. SCLC Treatment
- **Limited stage**:

- Chemotherapy + radiotherapy (cisplatin + etoposide)
- Prophylactic cranial irradiation
- **Extensive stage**:
- Chemotherapy ± immunotherapy
- Poor prognosis; median survival ~12 months

10. Prognosis
- **NSCLC**: 5-year survival ranges from 60% (stage I) to <5% (stage IV)
- **SCLC**: Very poor prognosis due to rapid progression and early spread

11. Recent Advances and Research Directions
- **Liquid biopsy** for non-invasive monitoring
- **Circulating tumor DNA (ctDNA)** detection
- **Tumor mutational burden (TMB)** as a biomarker for immunotherapy
- **Combination immunotherapies**
- **Neoantigen-based personalized cancer vaccines**
- **Radiomics and AI in imaging**
- **CRISPR and gene editing** for functional studies
- **Targeting tumor microenvironment**

12. Prevention and Screening
- **Smoking cessation**: Most effective prevention strategy
- **Occupational safety regulations**
- **Radon testing in homes**
- **Low-dose CT (LDCT) screening** for high-risk populations:
o Adults aged 50–80 with a 20+ pack-year smoking history

Brain Tumors: Detailed Overview

1. Definition
A **brain tumor** is an abnormal growth of cells within the brain or central nervous system (CNS). These tumors may be **primary** (originating in the brain) or **secondary/metastatic** (spread from another part of the body).

2. Epidemiology
- **Incidence**: ~300,000 new cases of primary brain and CNS tumors occur globally each year.
- **Age**: Some tumors are more common in children (e.g., medulloblastoma), while others predominate in adults (e.g., glioblastoma).
- **Gender**: Slight male predominance in malignant tumors; meningiomas are more common in females.

3. Classification of Brain Tumors
A. Based on Origin
- **Primary brain tumors**: Originate in the brain tissues.
- **Secondary (metastatic)** tumors: Arise elsewhere (e.g., lung, breast, melanoma) and spread to the brain.

B. Based on WHO Classification (2021 Update)
- Uses **histology + molecular markers** for classification.

Major types:
1. **Gliomas** (arising from glial cells)
- Astrocytomas (including **glioblastoma**, grade 4)
- Oligodendrogliomas
- Ependymomas

Meningiomas
- Arise from meninges; usually benign (WHO grade 1)

Medulloblastomas
- Malignant embryonal tumor; most common in children

Pituitary adenomas
- Tumors of the pituitary gland; usually benign

CNS lymphomas
- Primary or secondary; often seen in immunocompromised patients

Metastatic tumors
- Most common brain tumors in adults; originate from systemic cancers

4. Risk Factors
- **Genetic predisposition**:
- Li-Fraumeni syndrome

- Neurofibromatosis type 1 & 2
- Tuberous sclerosis
- von Hippel-Lindau disease
- **Radiation exposure**
- **Immunosuppression**
- **Environmental exposures** (less well established)
- **Age and sex** (certain tumors are age- and sex-specific)

5. Pathophysiology
- **Genetic mutations** (e.g., IDH1/2, TP53, EGFR)
- **Epigenetic changes** (e.g., MGMT promoter methylation)
- **Disruption of normal neural and glial cell cycle regulation**
- **Invasion of local brain tissue**, which complicates surgical resection
- **Increased intracranial pressure** due to mass effect

6. Clinical Presentation
General Symptoms
- Headache (often worse in the morning)
- Nausea/vomiting
- Seizures
- Cognitive or personality changes
- Vision or hearing disturbances
- Signs of increased intracranial pressure (ICP)

Focal Neurological Deficits
- Depend on tumor location:
- **Frontal lobe**: behavior, decision-making
- **Temporal lobe**: memory, language
- **Occipital lobe**: vision loss
- **Cerebellum**: coordination, balance
- **Brainstem**: cranial nerve deficits, autonomic functions

7. Diagnosis
A. Neuroimaging
- **MRI with contrast**: Gold standard for tumor visualization
- **CT scan**: Useful for emergencies, calcifications, and hemorrhages
- **MR spectroscopy and perfusion imaging**: Provides metabolic and vascular data

B. Biopsy
- Stereotactic biopsy if deep or inoperable
- Open biopsy during surgical resection

C. Molecular Testing
- IDH mutation status

- 1p/19q co-deletion (oligodendrogliomas)
- MGMT promoter methylation (predicts response to temozolomide)
- ATRX, TP53, TERT, and EGFR status

8. Grading (WHO System, 2021)
- **Grade I**: Benign (e.g., pilocytic astrocytoma)
- **Grade II**: Low-grade, slow-growing
- **Grade III**: Anaplastic, more aggressive
- **Grade IV**: Highly malignant (e.g., glioblastoma)

9. Treatment
A. Surgical Resection
- **Maximal safe resection** is preferred when possible
- Extent of resection correlates with prognosis

B. Radiation Therapy
- Used postoperatively or as primary therapy for inoperable tumors
- Techniques: Stereotactic radiosurgery (SRS), whole-brain radiation therapy (WBRT), proton beam therapy

C. Chemotherapy
- **Temozolomide (TMZ)**: Standard for glioblastoma
- **PCV regimen (procarbazine, CCNU, vincristine)** for oligodendrogliomas
- **Methotrexate**: For CNS lymphomas

D. Targeted and Immunotherapies
- **Bevacizumab (anti-VEGF)**: Used in recurrent glioblastoma
- **Checkpoint inhibitors**: Limited efficacy so far; under investigation
- **Tumor Treating Fields (TTF)**: Alternating electric fields to disrupt cancer cell division (FDA-approved for glioblastoma)

10. Prognosis
- **Varies by tumor type, grade, and molecular markers**
- **Glioblastoma**: Median survival ~15–18 months
- **Low-grade gliomas**: 5–10+ years with appropriate treatment
- **Meningiomas**: Excellent prognosis if benign and resectable
- **Metastatic brain tumors**: Depends on control of primary cancer

11. Recent Advances and Research Trends

- **Integration of molecular classification (IDH, 1p/19q, MGMT)** into WHO grading
- **Liquid biopsy** using cerebrospinal fluid (CSF) for tumor DNA
- **Immunotherapy trials**: Including CAR-T cell therapies for gliomas
- **Oncolytic viruses**: Engineered viruses that selectively kill tumor cells
- **Nanoparticle drug delivery** to cross the blood-brain barrier
- **Artificial intelligence in radiology**: Improved tumor characterization and outcome prediction

12. Prevention and Surveillance
- No known primary prevention for most brain tumors
- **Genetic counseling** for hereditary syndromes
- Regular **MRI screening** for high-risk individuals (e.g., NF1, tuberous sclerosis)

Major Categories of Cancer
1. Carcinomas
- **Origin**: Epithelial cells (which line internal organs and outer body surfaces)
- **Most common type of cancer**
- **Examples**:
- **Adenocarcinoma**: from glandular epithelial tissue (e.g., breast, colon, prostate)
- **Squamous cell carcinoma**: from squamous epithelium (e.g., skin, esophagus, lungs)
- **Basal cell carcinoma**: skin cancer arising from basal cells
- **Transitional cell carcinoma**: from urothelium (e.g., bladder cancer)

Sarcomas
- **Origin**: Connective or supportive tissues (bone, cartilage, fat, muscle, blood vessels)
- **Relatively rare**
- **Examples**:
- **Osteosarcoma**: bone
- **Chondrosarcoma**: cartilage
- **Liposarcoma**: fat
- **Rhabdomyosarcoma**: muscle

Leukemias
- **Origin**: Blood-forming tissues (bone marrow and blood)
- **Characterized by uncontrolled proliferation of abnormal white blood cells**
- **Examples**:
- **Acute lymphoblastic leukemia (ALL)**
- **Chronic lymphocytic leukemia (CLL)**

- **Acute myeloid leukemia (AML)**
- **Chronic myeloid leukemia (CML)**

Lymphomas
- **Origin**: Lymphatic system (lymph nodes, spleen, thymus, etc.)
- **Involve lymphocytes (T or B cells)**
- **Examples**:
- **Hodgkin lymphoma (HL)**: presence of Reed-Sternberg cells
- **Non-Hodgkin lymphoma (NHL)**: diverse group of B-cell and T-cell lymphomas

Myelomas
- **Origin**: Plasma cells in the bone marrow
- **Disrupts normal production of blood cells and causes bone lesions**
- **Example**:
- **Multiple myeloma**

Central Nervous System (CNS) Tumors
- **Origin**: Brain and spinal cord tissues
- May be benign or malignant; both can be life-threatening due to location
- **Examples**:
- **Glioblastoma multiforme**
- **Astrocytoma**
- **Meningioma**
- **Medulloblastoma**

Germ Cell Tumors
- **Origin**: Reproductive cells (testes, ovaries, or extragonadal sites)
- Often occur in children and young adults
-
- **Examples**:
- **Testicular seminoma**
- **Ovarian dysgerminoma**
- **Teratomas**
Neuroendocrine Tumors (NETs)
- **Origin**: Cells that release hormones into the blood in response to signals from the nervous system
- Can be benign or malignant
- **Examples**:
- **Carcinoid tumors**
- **Pancreatic neuroendocrine tumors**
- **Small cell lung cancer (a type of neuroendocrine carcinoma)**

MAJOR CAUSES OF CANCER
1. Genetic Factors (Inherited)

- **Inherited mutations** passed from parents to children (5–10% of all cancers)
- Examples:
- **BRCA1 and BRCA2**
mutations → breast and ovarian cancer
- **TP53** mutation (Li-Fraumeni syndrome)
- **APC** mutation (familial adenomatous polyposis → colon cancer)
- **RET, MLH1, MSH2** (linked to endocrine and colorectal cancers)

2.   Environmental and Lifestyle Factors
A.   Tobacco Use
- **Leading preventable cause   of cancer**
- Contains carcinogens like benzene, formaldehyde, nitrosamines
- Associated cancers:
- Lung, mouth, throat, esophagus, bladder, kidney, pancreas
B.   Diet and Obesity
- High-fat, low-fiber diets
- Processed meats (classified as Group 1 carcinogens by WHO)
- Obesity increases risk of:
- Breast, colon, endometrial, kidney, pancreatic, and liver cancers
C.   Alcohol Consumption
- Increases risk of cancers of the:
- Oral cavity, pharynx, larynx, esophagus, liver, breast, and colon
D.   Physical Inactivity
- Sedentary lifestyle linked to obesity- related cancers

3.   Infectious Agents
- ~15–20% of cancers globally are linked to infections
- Examples:
- **Human papillomavirus (HPV)** → cervical, anal, throat cancers
- **Hepatitis B and C (HBV, HCV)** → liver cancer
- **Epstein-Barr virus (EBV)** → nasopharyngeal carcinoma, some lymphomas
- **Helicobacter pylori** → stomach cancer
- **HIV/AIDS** → Kaposi's sarcoma,   non-Hodgkin lymphoma

4.   Occupational and Environmental Exposures
- **Asbestos** → mesothelioma
- **Benzene** → leukemia
- **Formaldehyde** → nasopharyngeal cancer, leukemia
- **Radiation (ionizing and UV)**
- X-rays, radon   gas   →   leukemias and other cancers
- UV   light   →   skin cancers including melanoma

5.   Hormonal Factors
- **Endogenous or exogenous hormones** can influence cancer risk:
- Estrogens → breast, endometrial cancer
- Testosterone → prostate cancer
- Hormone replacement therapy (HRT) and oral contraceptives carry some risk

6.   Immunosuppression
- Weakened immune systems (e.g., post-transplant, HIV) increase cancer risk
- Common cancers: Kaposi's sarcoma, lymphomas, skin cancers

7.   Chronic Inflammation and Medical Conditions
- Chronic inflammatory diseases increase cancer risk:
- Inflammatory bowel disease
→ colorectal cancer
- Chronic hepatitis → liver cancer
- GERD → esophageal adenocarcinoma

8.   Age and Gender
- Cancer risk increases with age due to accumulated genetic damage and immune decline
- Certain cancers are more common by sex (e.g., prostate in men, breast in women)

9.   Random (Spontaneous) Mutations
- Some cancers arise without a clear external cause, due to random DNA errors during cell division

Cause Category	Example Factors	Related Cancers
Genetic Life style Infections	BRCA1/2, TP53, APC mutations Smoking, alcohol,	Breast, colon, ovarian Lung, liver, colorectal, breast
Environmental	diet, obesity HPV, HBV,	Cervical, liver, gastric,
Hormonal	H.pylori, EBV Asbestos,	lymphoma
Immunesuppression	benzene, UV, radiation	Mesothelioma, leukemia, skin
Inflammation	Estrogen, testosterone	cancers
Age-related	HIV, transplant drugs	Breast, prostate, endometrial
Random errors	IBD, hepatitis, GERD	Lymphoma, Kaposi's sarcoma
	Natural aging process	Colorectal, liver, esophageal
	DNA replication mistakes	Most cancers Any tissue type

Treatment Modalities:

Surgery: Removal of the tumor or affected tissue.

Chemotherapy: Use of drugs to kill cancer cells or stop their growth.

Radiation Therapy: Use of radiation to kill cancer cells or shrink tumors.

Targeted Therapy: Drugs that target specific molecules involved in cancer cell growth or survival.

Hormone Therapy: Use of drugs to block the effects of hormones that may fuel cancer growth.

Immunotherapy: Use of the body's own immune system to fight cancer.

Bone Marrow Transplant: Replacement of damaged bone marrow with healthy marrow.

Cryoablation: Freezing and destroying tumor tissue.

Other Therapies: Laser therapy, photodynamic therapy, and other emerging therapies.

Diagnostic Methods:

Imaging: CT scans, MRI, PET scans, ultrasounds, and X-rays to visualize tumors and assess their spread.

Biopsy: Collection of tissue or cell samples for microscopic examination.

Blood Tests: Analysis of blood samples to detect abnormal proteins or other markers. **Staging and Prognosis:**

Staging:

Determining the extent of cancer spread, which influences treatment decisions and prognosis.

Prognosis:

Estimating the likely course and outcome of the disease, often based on factors like stage, grade, and patient characteristics.

Research and Development:

Ongoing research is focused on improving existing therapies, developing new targeted therapies, and finding better ways to prevent and detect cancer.

Cancer research includes the development of new diagnostic tools, imaging techniques, and drug delivery systems.

Research also explores the role of genetics, environmental factors, and lifestyle choices in cancer development.

Pharmacological of Cancer

• "Pharmacological Advances in Cancer Therapy: Mechanisms and Drug Development"

• "Targeted Cancer Pharmacology: From Molecular Pathways to Clinical Applications"

• "Chemotherapeutic Agents and Novel Drug Delivery Systems in Cancer Treatment: A Review"

• "Pharmacokinetics and Pharmacodynamics of Anticancer Drugs: Current Insights"

• "Immunopharmacology in Cancer: Harnessing the Immune System for Therapeutic Gain"

• "Overcoming Drug Resistance in Cancer Pharmacology: Strategies and Challenges"

• "The Role of Small Molecule Inhibitors and Biologics in Modern Cancer Pharmacology"

Cancer Diagnosed

1. **Medical History and Physical Exam**

• A doctor asks about symptoms, family history, lifestyle factors, and risk exposures (like smoking or sun exposure).

• Physical examination is done to check for lumps, swelling, or other unusual signs.

2. **Laboratory Tests**

• **Blood tests**: To detect abnormal blood cells, organ function, or tumor markers (e.g., PSA for prostate cancer, CA-125 for ovarian cancer).

• **Urine or other bodily fluids**: May also show signs of cancer.

3. Imaging Tests
These help locate tumors and determine their size and spread:
- **X-rays**
- **CT scans** (computed tomography)
- **MRI** (magnetic resonance imaging)
- **Ultrasound**
- **PET scans** (positron emission tomography)

4. Biopsy (Most Definitive Test)
- A **sample of tissue** is taken from the suspicious area.
- Examined under a microscope by a **pathologist** to confirm if cancer cells are present.
- Types:

o **Needle biopsy** (uses a thin needle)
- Often used after surgery to kill remaining cancer cells.
- **Surgical biopsy** (removal of _____ part or all of a lump)
- **Endoscopic biopsy** (via a camera inserted into body cavities)

5. Molecular and Genetic Testing
- Determines if the cancer has specific mutations (e.g., BRCA genes in breast cancer).
- Helps guide targeted therapy or immunotherapy.

6. Staging Tests
Once cancer is confirmed, additional tests may be done to find out **how far it has spread** (staging).

Treatment
1. Surgery
- **Purpose**: Remove the tumor and nearby affected tissue.
- Common for solid tumors (e.g., breast, colon, lung).
- Sometimes used with other treatments like radiation or chemotherapy.

2. Chemotherapy
- **Purpose**: Use drugs to kill or slow the growth of cancer cells.
- Can be given orally or through injection.
- Often used for cancers that have spread or to shrink tumors before surgery.

3. Radiation Therapy
- **Purpose**: Use high-energy rays (like X-rays) to kill cancer cells.
- Can be external (from a machine) or internal (radioactive material placed near the tumor).

4. Targeted Therapy
- **Purpose**: Attack specific molecules involved in cancer cell growth.
- Fewer side effects than chemotherapy.
- Used for cancers with specific genetic changes (e.g., HER2-positive breast cancer).

5. Immunotherapy
- **Purpose**: Helps the body's immune system recognize and destroy cancer cells.
- Used in cancers like melanoma, lung cancer, and certain blood cancers.
- Includes checkpoint inhibitors, CAR T-cell therapy, and cancer vaccines.

6. Hormone Therapy
- **Purpose**: Block hormones that fuel certain cancers (e.g., breast, prostate).
- Includes drugs or surgery to remove hormone-producing organs.

7. Stem Cell or Bone Marrow Transplant
- **Purpose**: Replace damaged bone marrow (often after high-dose chemotherapy or radiation).
- Common in blood cancers like leukemia and lymphoma.

8. Palliative Care
- **Purpose**: Relieve symptoms and improve quality of life.
- Can be combined with curative treatment or used alone in advanced cancer.

Personalized Treatment
Modern cancer care often involves a **combination of treatments**, tailored to the individual through a **multidisciplinary team** of oncologists, surgeons, and other specialists.

II.   CONCLUSION
Cancer is a complex group of diseases characterized by uncontrolled growth and spread of abnormal cells. Early diagnosis through screening and tests is crucial for effective treatment. Treatment options vary widely depending on the type and stage of cancer and may include surgery, chemotherapy, radiation, targeted therapy, immunotherapy, or a combination of these. Advances in medical research continue to improve

cancer detection, treatment, and patient outcomes. Despite its challenges, many cancers are treatable and even curable, especially when detected early.

Cancer detection and diagnosis involve a combination of medical history, physical exams, imaging tests, laboratory tests, and most importantly, biopsy to confirm the presence of cancer cells. Early and accurate diagnosis is critical to choosing the best treatment approach. Cancer treatment varies based on the type and stage of cancer and may include surgery, chemotherapy, radiation, targeted therapy, immunotherapy, or hormone therapy. Personalized treatment plans and advances in medical technology have improved survival rates and quality of life for many patients. Early detection and timely treatment remain key factors in successfully managing cancer.

REFERENCES
[1]. National institute of health (US); Biological sciences curriculum study. NIH curriculum supplement series [internet]. Bethesda (MD): National institutes of Health (US); 2007. Understanding cancer.
[2]. How cancer arises, Robert A. Weinberg, Fundamental understandings, scientific American, sept-1996.
[3]. Cancer: Science and society. J. Cairns, W.H. Freeman, 1978.
[4]. Genes and the biology of cancer. H. Varmus and R. A. Weinberg, Scientific American library, 1993.
[5]. Cancer: The rise of the genetic paradigm. J. M. Bishop in genes and development, vol 9, No 14, pages 1309-1315, June 1, 1995.
[6]. Oncogenes. Second edition. G. M. Cooper. Jones and Bartlett publishers, Boston, 1995.
[7]. Immuno-Oncology agents for cancer therapy, Sophie carter and David E. Thurston, The Pharmaceutical Journal, cancer, Vol 304, No 7937, May 2020. Pp S2-S27.
[8]. Cancer Undefeated. John C. Bailar, Heather L. Gornik, New England Journal of Medicine, Vol 336, Issue 22, pp 1569-1574, 1997.
[9]. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Katherine a Hoadley, et.al., Cell, vol 173, issue 2, pp 291-304, e6, 2018.
[10]. Plasma free amino acid profiling of five types of cancer patients and its application for early detection. Yohei Miyagi, et.al., Plos one, Vol 6, Issue 9, e24143, 2011.
[11]. A mathematical model for the age distribution of cancer in man. Philip J. Cook, et.al., International Journal of cancer, Vol 4, Issue 1, pp 93-112, 1969. **IJRPAS, Nov-Dec 2022;**
[12]. **1(3): 42-49** Jayesh M. Rajput,
[13]. **Cancer: A Comprehensive Review**
[14]. Prostaglandins as mediators of hypercalcemia associated with certain types of cancer. Hannsjoerg W. Seyberth, et.al., New England Journal of Medicine, Vol 293, Issue 25, pp 1278-1283, 1975.
[15]. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Frederic Chibon, et.al., Nature medicine, Vol 16, Issue 7, pp 781-787, 2010.
[16]. Relationship between exposure to radon and various types of cancer. Bernard L. Cohen, Health Physics, Vol 65, Issue 5, pp 529-531, 1993.
[17]. Various types and management of breast cancer: an overview. Ganesh N Sharma, et.al., Journal of advanced pharmaceutical technology and research, vol 1, issue 2, pp 109, 2010.
[18]. Review of cancer from perspective of molecular. Sayed Hossein Hassanpour, et.al., Journal of Cancer research and practice, Vol 4, Issue 4, pp 127-129, 2017.

National Cancer Institute (NCI)
- Website: https://www.cancer.gov
- Offers comprehensive, up-to-date information on cancer types, treatments, clinical trials, and research.

World Health Organization (WHO) – Cancer
- Website: https://www.who.int/health-topics/cancer
- Provides global cancer statistics, prevention strategies, and policy guidelines.

American Cancer Society (ACS)
- Website: https://www.cancer.org
- A trusted resource for patient education, cancer detection, treatment options, and support.

PubMed
- Website: https://pubmed.ncbi.nlm.nih.gov

- A database of millions of peer-reviewed scientific articles on cancer research and clinical studies.

Cancer Research UK
- Website: https://www.cancerresearchuk.org
- Offers research findings, statistics, and guidance on cancer prevention and treatment.

The Lancet Oncology
- Website: https://www.thelancet.com/journals/lanonc
- A leading medical journal publishing high-impact cancer research.